Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (March 2022)
20 slides from Cynata Therapeutics's investor presentation, Mar 8, 2022
Slide 1: Updated Investor Presentation ASX Announcement
ASX ANNOUNCEMENT 8 March 2022 Updated Investor Presentation For personal use only Melbourne, Australia; 8 March 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to release an updated Corpo
Slide 2: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company Investor Presentation (March 2022)
Slide 3: Investment Highlights
Investment Highlights Cynata is a clinical stage biotech developing its proprietary CymerusTM platform technology for the scalable manufacture of mesenchymal stem cell (MSC) therapeutic products to treat serious disorders For personal use only Unique Strong safety Multiple Large Significant Manufact
Slide 4: Why MSCs?
Why MSCs? MSCs play a central co-ordinating role in many of the body’s mechanisms of defence, repair and regeneration: 1 the “sensor and switcher of the immune system” For personal use only Global interest in MSCs continues to grow >1,0002 clinical trials of MSCs have been initiated in the past deca
Slide 5: Conventional vs. Cynata's Cymerus MSC manufacturing process
Conventional vs. Cynata’s Cymerus MSC manufacturing process Cells donated Conventional process MSCs For personal use only Cells from Limited quantity Significant MSC 1 multiple donors 2 of MSCs isolated 3 expansion required 4 Cell therapy product Conventional Processes Cells donated Cynata’s patente
Slide 6: Cymerus Platform Summary
Cymerus Platform Summary TM Cynata is focused on the development of MSC-based therapeutic products using its unique proprietary Cymerus manufacturing technology For personal use only Cymerus Technology Key Advantages • A process for generating a range of MSC-based cell therapy products derived from
Slide 7: Cynata's technology addresses FDA concerns
Cynata’s technology addresses FDA concerns Cynata’s Cymerus process actively addresses current inefficiencies of MSC manufacturing, de-risking clinical development in the US For personal use only Traditional MSC manufacturing is sub-optimal Cynata’s technology is optimal Other MSC therapy (also targ
Slide 8: Cynata has an advanced and diverse product pipeline
Cynata has an advanced and diverse product pipeline Compelling safety results from Phase 1 GvHD trials1 and positive preclinical data in each target indication have accelerated the pipeline For personal use only Pre-clinical Phase 1 / Phase 2 Phase 3 Funded by Osteoarthritis Phase 3 underway NHMRC M
Slide 9: SPA with Fujifilm provides commercial benefits
SPA with Fujifilm provides commercial benefits Cynata executed a Strategic Partnership Agreement with Fujifilm, with Fujifilm remaining very supportive of Cynata and involved in the path to market1 For personal use only Key SPA terms • US$5m fee paid by Fujifilm to Cynata • Cynata regained all devel
Slide 10: GvHD | Ground-breaking Phase 1 clinical trial results
GvHD | Ground-breaking Phase 1 clinical trial results Cynata’s Phase 1 GvHD trial met all safety and efficacy endpoints and broke ground by being the world’s first clinical trial of an allogeneic iPSC-derived product For personal use only Key results1 demonstrate safety and efficacy of Cymerus MSCs
Slide 11: Accelerate US development strategy for GvHD
Accelerate US development strategy for GvHD Cynata is aiming to progress a Phase 2 GvHD clinical trial in the US, after regaining clinical and commercial rights to CYP-001 in GvHD as part of the SPA with Fujifilm For personal use only Orphan Drug Phase 1 trial SPA with Phase 2 trial Engage with Comm
Slide 12: SCUlpTOR | Osteoarthritis Phase 3 clinical trial
SCUlpTOR1 | Osteoarthritis Phase 3 clinical trial Clinical trial underway, sponsored by the University of Sydney and funded by an NHMRC project grant For personal use only • Osteoarthritis (OA) occurs when the cartilage in a joint wears away Key Milestones Osteoarthritis • Causes pain, inflammation,
Slide 13: MEND | Clinical trial in respiratory distress
MEND1 | Clinical trial in respiratory distress Patient recruitment underway, following expansion of patient population to increase pool of potential subjects For personal use only • Respiratory Failure is a collection of signs and symptoms which Key Milestones Respiratory collectively can be known a
Slide 14: DFU | Clinical trial in diabetic foot ulcers
DFU | Clinical trial in diabetic foot ulcers Recruitment has commenced and the trial is open for enrolment For personal use only Key Milestones Diabetic Foot • DFU are sores on the feet of patients with diabetes (also known as Ulcers (DFU) diabetic wounds) Sign licence Completed with TekCyte • >400m
Slide 15: Significant market opportunities
Significant market opportunities Cynata is targeting attractive market opportunities across a range of target indications For personal use only Target area Market opportunity Osteoarthritis (OA) US$11.6bn1 Acute Respiratory Distress Syndrome (ARDS) Cytokine Release Syndrome (CRS) US$8.4bn2,3,4 Sepsi
Slide 16: Near term catalysts
Near term catalysts Cynata is in a strong position to advance development of its proprietary Cymerus platform For personal use only technology ❑ Complete recruitment of 30 patients in DFU trial ❑ Complete recruitment of 24 patients in MEND (respiratory failure) trial ❑ Advance US Regulatory strategy
Slide 17: Board & management
Board & management Highly skilled and experienced senior leadership team with decades of experience in biotechnology For personal use only Dr Geoff Brooke Dr Ross Macdonald Dr Kilian Kelly Dr Jolanta Airey Chairman Managing Director / CEO Chief Operating Officer Chief Medical Officer • 30+ years exp
Slide 18: Corporate overview
Corporate overview Cynata is proud to be supported by major institutional investors and the Company remains well funded and debt free For personal use only Shareholder distribution Major institutional shareholders Bioscience Managers 10.0% 49% Fidelity Fidelity International is a world leading inves
Slide 19: Important information
Important information Summary information ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries expressions. The forward looking statem
Slide 20: Contact Us
For personal use only Contact Us Cynata Therapeutics Limited Contact details: Level 3 100 Cubitt Street ross.macdonald@cynata.com Cremorne Victoria 3121 www.cynata.com Australia
Cynata Therapeutics — Investor Presentation (March 2022) on 6ix